CPR Invest - European Strategic Autonomy - A EUR - Acc ISIN : LU2570611322

CPR Invest - European Strategic Autonomy - A EUR - Acc
A EUR(C) - LU2570611322
Asset class: Equities

YTD
As of 18/11/2026
5.01%

Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.

NAV
As of 18/11/2026
€142.92

SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8

Fund AUM
As of 18/11/2026
€1.08B
The investment objective is to outperform European equity markets over a long-term period (minimum of five years) by investing in equities involved in strategic sectors that contribute to Europe’s autonomy and resilience, while integrating Environmental, Social and Governance (ESG) criteria in the investment process.
 

NAVs

NAV from 28/03/2023 to 18/11/2026
Select period
Created with Highcharts 11.4.8CPR Invest - European Strategic Autonomy - A EUR - AccApr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26Oct '2680100120140160180

Performance

Change in NAV in base 100
FundCPR Invest - European Strategic Autonomy - A EUR - Acc (42.92% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - European Strategic Autonomy - A EUR - AccBenchmarkApr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26Oct '2680100120140160180
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
FundCPR Invest - European Strategic Autonomy - A EUR - Acc (42.92% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - European Strategic Autonomy - A EUR - AccBenchmarkApr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26Oct '2680100120140160180
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.

Portfolio Analysis

Repartition 10/31/2026
Sector
Weight
Spread / Index
ASML HOLDING NVInformation Technology7.91%-1.04%
SIEMENS AG-REGIndustrials3.29%0.25%
BANCO SANTANDER SA MADRIDFinancials3.25%0.95%
AIRBUS SE PARISIndustrials2.91%1.12%
SAP SE / XETRAInformation Technology2.83%-0.42%
ALLIANZ SE-REGFinancials2.67%0.11%
COMPAGNIE DE SAINT GOBAINIndustrials2.67%2.21%
SAFRAN SAIndustrials2.50%1.03%
COMMERZBANK AGFinancials2.45%2.10%
SCHNEIDER ELECT SEIndustrials2.43%0.34%

Management commentary

Effective date: 31/10/2026
In October, the fund recorded a performance of -3.13%, compared to -1.58% for the MSCI EMU Net Total Return index. Year-to-date, the fund is up 6.41%, versus 9.06% for its benchmark index.
 
The start of the season was particularly eventful, both from a geopolitical perspective with the ongoing stalemate between the United States and Iran. President Trump publicly hinted that the time for a decision was approaching, wavering between concluding an agreement or resuming military operations against Tehran. The price of a barrel continued its upward trajectory begun in June, with a monthly increase of 13.6%. Brent futures are now trading at $100 levels until next May. Inflation therefore remains high; in Europe, it was 3.8%, driven by energy prices. In this context, purchasing power is deteriorating and protests have multiplied across Europe, particularly in France. Added to this were concerns related to AI financing. The catalyst was the surge in Coreweave’s CDS. The risk of a credit bubble forming in Neoclouds had a contagion effect across the entire technology sector. The dependence on capex and the credit market to finance them is worrying.
 
In this context, stocks related to electrification were heavily penalized both within technology (ASML, ASMI, and Infineon down by 11.41%, 17.82%, and 15.03% respectively) and within industrials (Siemens Energy, Legrand, Prysmian down by 11%, 10.97%, and 7.49%). The defense sector rebounded slightly, but engine manufacturers suffered particularly from tensions in oil prices; thus, Safran and Roll-Royce fell by 17.55% and 12.99%. The healthcare sector, as in the previous month, was a detractor, with significant declines from Abivax and Ottobock, down by -9.97% and -9.32% respectively.
Ingredients performed well over the month following strong earnings releases; DSM and Novonesis rose by 9.4% and 10.16%.
 
Regarding portfolio movements, we slightly increased our position in Safran after its earnings release. We initiated a position in EssilorLuxottica by selling our Carrefour shares.

Characteristics

General data

Inception date
28/03/2023
First Nav Date
28/03/2023
Currency
EUR
Show more
Valuation
Daily
Minimum initial investment
1 10/1000° share(s)/equity
Minimum additional investment
1 10/1000° share(s)/equity

Costs Composition

One-off costs upon entry or exit (Investment EUR 10,000)If you exit after 1 year
Entry costsThis includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge.Up to €500.00
Exit costsWe do not charge an exit fee for this product, but the person selling you the product may do so.€0.00
Ongoing costs taken each year (Investment EUR 10,000)
Management fees and other administrative or operating costs1.96% of the value of your investment per year. This percentage is based on actual costs over the last year.€186.49
Transaction costs0.24% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.€22.86
Incidental costs taken under specific conditions (Investment EUR 10,000)
Performance fees

15.00% annual outperformance of the reference asset 100% MSCI EMU NR Close. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.

The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset.

€4.09

Codification

ISIN code
LU2570611322
Bloomberg code
CPEUSTA LX
Reuters code

Investment Objective

The investment objective is to outperform European equity markets over a long-term period (minimum of five years) by investing in equities involved in strategic sectors that contribute to Europe’s autonomy and resilience, while integrating Environmental, Social and Governance (ESG) criteria in the investment process.
 

Documents

LanguageDocumentsTypeClosing Date
CS
PDF
01/09/2026
PDF
01/10/2026
EN
PDF
31/07/2025
PDF
31/01/2026
CS
PDF
31/10/2026
EN
PDF
26/10/2016
Prices expressed in a currency other than the base currency of the portfolio are available for information purposes only.
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.